Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21;17(7):e0270956.
doi: 10.1371/journal.pone.0270956. eCollection 2022.

Bone marrow involvement in patients with metastatic castration sensitive prostate cancer

Mohammed Shahait  1 , Ramiz Abu-Hijlih  2 , Alaa Salamat  3 , Nassib Abou Heidar  4 , Baha' Sharaf  3 , Fawzi Abuhijla  2 , Samer Salah  3
Affiliations

Bone marrow involvement in patients with metastatic castration sensitive prostate cancer

Mohammed Shahait et al. PLoS One. .

Abstract

Introduction: The clinical significance of bone marrow (BM) metastasis in prostate cancer as well as impact on oncological prognosis is unclear. We aim to assess the prevalence and clinical outcomes of BM metastasis at initial presentation of metastatic castrate sensitive prostate cancer (CSPC).

Patients and methods: Retrospective chart review of newly diagnosed metastatic CSPC patients was performed with collection of clinicopathologic and radiologic characteristics. Descriptive univariate and multivariate analysis was performed as well as survival measures (OS and PFS), which was done using the Kaplan-Meier survival and the Log-rank test.

Results: 189 patients were eligible, of which, eleven patients (6%) had biopsy proven BM involvement at diagnosis. There was a trend to poorer PFS and OS in patients with BM involvement but not statistically significant; however, factors that correlated with inferior PFS and OS in the multivariate analysis included ECOG PS, ALP, and Hb.

Conclusion: BM metastasis in prostate cancer may lead to poorer survival. Clinical features including poor performance status, anemia, and elevated ALP, could guide bone marrow biopsies in the future to diagnose bone marrow metastasis at an earlier stage.

PubMed Disclaimer

Conflict of interest statement

All the authors declare no conflict of interest.

Figures

Fig 1
Fig 1. Kaplan-Meier estimation of time to PSA progression according to presence of bone marrow metastasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al.. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology. 2017;3(4):524–48. doi: 10.1001/jamaoncol.2016.5688 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7–34. - PubMed
    1. Morash C, Tey R, Agbassi C, Klotz L, McGowan T, Srigley J, et al.. Active surveillance for the management of localized prostate cancer: Guideline recommendations. Canadian Urological Association journal = Journal de l’Association des urologues du Canada. 2015;9(5–6):171–8. doi: 10.5489/cuaj.2806 - DOI - PMC - PubMed
    1. Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al.. Visceral disease in castration-resistant prostate cancer. European urology. 2014;65(2):270–3. doi: 10.1016/j.eururo.2013.10.055 - DOI - PMC - PubMed
    1. Park DS, Hwang JH, Kang MH, Oh JJ. Association between R.E.N.A.L. nephrometry score and perioperative outcomes following open partial nephrectomy under cold ischemia. Canadian Urological Association journal = Journal de l’Association des urologues du Canada. 2014;8(3–4):E137–41. doi: 10.5489/cuaj.1372 - DOI - PMC - PubMed